Insmed stocks soar as Phase III lung disease drug exceeds expectations [Yahoo! Finance]
Insmed Incorporated (INSM)
Last insmed incorporated earnings: 4/30 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.insmed.com
Company Research
Source: Yahoo! Finance
The highly anticipated ASPEN trial (NCT04594369) was a global, randomised, double-blind, placebo-controlled Phase III study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis. Following the announcement, the companies' stocks rocketed from $22.00 at close on May 24 to $49.65 at open on May 28. The price peaked on May 28 at $50.10. Given the highly successful trial, the company will be filing a New Drug Application (NDA) with the US Food and Drug Administration (FDA) before the end of the year. If approved, brensocatib would be the first approved treatment for patients with bronchiectasis as well as the first approved dipeptidyl peptidase 1 (DPP1) inhibitor. Insmed anticipates a US launch for brensocatib in mid-2025 followed by launches in Europe and Japan in the first half of 2026. If approved, GlobalData forecasts that global sales of the pipeline candidate could hit $1.2bn in 2030. GlobalData is the parent
Show less
Read more
Impact Snapshot
Event Time:
INSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INSM alerts
High impacting Insmed Incorporated news events
Weekly update
A roundup of the hottest topics
INSM
News
- Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Evercore ISI from $42.00 to $75.00. They now have an "outperform" rating on the stock.MarketBeat
- Insmed Incorporated (NASDAQ: INSM) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at JPMorgan Chase & Co. from $55.00 to $72.00. They now have an "overweight" rating on the stock.MarketBeat
- Non-cystic Fibrosis Bronchiectasis Drug Pipeline Market 2024 Featuring Zambon, AstraZeneca, Insmed, NovaBiotics, Haisco Pharmaceutical, Armata Pharmaceuticals, Chiesi Farmaceutici, & CSL Behring [Yahoo! Finance]Yahoo! Finance
- Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Mizuho from $36.00 to $82.00. They now have a "buy" rating on the stock.MarketBeat
INSM
Earnings
- 5/9/24 - Beat
INSM
Sec Filings
- 6/13/24 - Form 8-K
- 6/12/24 - Form 4
- 6/5/24 - Form 4
- INSM's page on the SEC website